Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15W7, Kita-Ku, Sapporo, 060-8638, Japan.
Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, Osaka Prefectural Hospital Organization, Osaka, Japan.
J Bone Miner Metab. 2021 Sep;39(5):804-809. doi: 10.1007/s00774-021-01219-0. Epub 2021 Apr 5.
Hypophosphatasia (HPP) is caused by mutations in the ALPL gene encoding tissue nonspecific alkaline phosphatase (TNSALP) and inherited in either an autosomal recessive or autosomal dominant manner. It is characterized clinically by defective mineralization of bone, dental problems, and low serum ALP levels. In the current report, we demonstrate a novel mutation in the ALPL gene (c.244G > A p.Gly82Arg) in a Japanese family with low serum ALP levels.
The ALPL gene analysis using hybridization capture-based next-generation sequencing was performed. The expression plasmids of the wild type and mutated TNSALP were introduced into COS-7 cells. The enzymatic activity of ALP in the cell lysates was measured using p-nitrophenylphosphate as a substrate.
TNSALP with the novel ALPL mutation (c.244G > A p.Gly82Arg) completely lost its enzymatic activity and suppressed that of wild-type TNSALP, corroborating its dominant negative effect. The diagnosis of autosomal dominant HPP was confirmed in three members of the family.
Our approach would help to avoid the inappropriate use of bone resorption inhibitors for currently mis- or under-diagnosed HPP, given that the presence of further, yet undetected mutations of the ALPL gene are plausible.
低磷酸酯酶症(HPP)是由编码组织非特异性碱性磷酸酶(TNSALP)的 ALPL 基因突变引起的,以常染色体隐性或常染色体显性遗传方式遗传。其临床特征为骨骼矿化缺陷、牙齿问题和血清 ALP 水平降低。在本报告中,我们在一个日本低血清 ALP 水平的家族中发现了 ALPL 基因的一个新突变(c.244G > A p.Gly82Arg)。
使用杂交捕获的基于下一代测序的 ALPL 基因分析。将野生型和突变型 TNSALP 的表达质粒导入 COS-7 细胞。用对硝基苯磷酸作为底物测量细胞裂解物中 ALP 的酶活性。
具有 novel ALPL 突变(c.244G > A p.Gly82Arg)的 TNSALP 完全丧失其酶活性,并抑制野生型 TNSALP 的活性,证实其具有显性负效应。该家族的三名成员被确诊为常染色体显性 HPP。
鉴于可能存在进一步尚未检测到的 ALPL 基因突变,我们的方法有助于避免对当前误诊或漏诊的 HPP 不恰当地使用骨吸收抑制剂。